Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Dr Clément BECLE Cardiologique – Centre Cardiologique de l’Ouest Lyonnais – Lyon https://pubmed.ncbi.nlm.nih.gov/33220323/ PMID : 33220323
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
Dr Martin NICOL : Cardiologue APHP Lariboisière – Paris https://pubmed.ncbi.nlm.nih.gov/35292807/ PMID : 35292807
Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis
Dr Damien EYHARTS : Cardiologue CHU de Toulouse Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis https://pubmed.ncbi.nlm.nih.gov/35178887/ PMID : 35178887
ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study
Pr François ROUBILLE : Cardiologue resp. équipe médicale insuffisance cardiaque – CHU de Montpellier ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study. https://pubmed.ncbi.nlm.nih.gov/35048207/ PMID : 35048207
Utilization and tolerance of beta-blockers among patients with AL amyloidosis.
Jean-Jacques VON HUNOLSTEIN : Cardiologue Hopital Civil STRASBOURG Utilization and tolerance of beta-blockers among patients with AL amyloidosis. https://pubmed.ncbi.nlm.nih.gov/34549676/ PMID : 34549676
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatmen
Antoine JOBBE-DUVAL : Cardiologue HCL LYON Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. https://pubmed.ncbi.nlm.nih.gov/34768388/ PMID : 34768388
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
Emmanuelle BERTHELOT : adjointe chef de service, Cardiologue – APHP CHU Bicêtre Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/32729170/ PMID : 32729170
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Patricia RÉANT : Cardiologue – CHU de BORDEAUX Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. https://pubmed.ncbi.nlm.nih.gov/34923848/ PMID : 34923848
Mode of death and outcomes of implantable cardioverter defibrillators in transthyretin amyloid cardiomyopathy
Frédéric MOUQUET : Cardiologue CHU de Lille https://pubmed.ncbi.nlm.nih.gov/34843821/
Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis
Jean-Pierre GUEFFET : Cardiologue Hôpital Privé du Confluent – Nantes https://pubmed.ncbi.nlm.nih.gov/34734/